Quick Answer
NEUROONE MEDICAL TECHNOLOGIES Corp reported Cash And Cash Equivalents At Carrying Value of $6.57 million for the year ending 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed an increase of +350.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from NEUROONE MEDICAL TECHNOLOGIES Corp's annual report (Form 10-K), filed with the SEC on December 17, 2025.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $70.0 thousand | Q1 2018: $25.2 thousand | Q2 2018: $22.6 thousand | Q4 2018: $350.6 thousand | Q1 2019: $2.31 million | Q2 2019: $1.25 million | Q4 2019: $2.04 million | Q1 2020: $747.2 thousand | Q2 2020: $3.82 million | Q3 2020: $4.04 million | Q4 2020: $7.13 million | Q1 2021: $11.27 million | Q2 2021: $8.99 million | Q4 2021: $16.18 million | Q1 2022: $12.87 million | Q2 2022: $10.18 million | Q4 2022: $4.67 million | Q1 2023: $3.60 million | Q2 2023: $3.08 million | Q4 2023: $2.68 million | Q1 2024: $2.43 million | Q2 2024: $1.62 million | Q4 2024: $1.13 million | Q1 2025: $1.32 million | Q2 2025: $8.04 million | Q3 2025: $6.57 million | Q4 2025: $3.56 million.
- Over the full 9 years of available data (2017 to 2025), NEUROONE MEDICAL TECHNOLOGIES Corp's Cash And Cash Equivalents At Carrying Value has grown by 24,724.8%.
- Historical annual values: Fiscal year 2025: $6.57 million | Fiscal year 2024: $1.46 million | Fiscal year 2023: $5.32 million | Fiscal year 2022: $8.16 million | Fiscal year 2021: $6.90 million | Fiscal year 2020: $4.04 million | Fiscal year 2019: $260.7 thousand | Fiscal year 2018: $13.3 thousand | Fiscal year 2017: $26.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: